Benitec Biopharma (BNTC) AI Stock Analysis

• Market Cap: $403.66M
• Dividend Yield: N/A
• Average Volume (3M): 175.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: N/A
• EPS Growth: 80.95%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 34,354,336
• 10 Day Avg. Volume: 233,047
• 30 Day Avg. Volume: 175,893
• PEG Ratio: 0.18
• Price to Book (P/B): 4.35
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.95
• Enterprise Value/Market Cap: 0.30
• Enterprise Value/Revenue: 216.91
• Enterprise Value/Gross Profit: -1.83K
• Enterprise Value/Ebitda: -2.35
• 1Y Price Target: $32.00
• Price Target Upside: 172.34% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -1.14
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $11.50 ▼(-2.13% Downside)
• Action: Reiterated Date: 02/14/26
• Date: Action: Reiterated 02/14/26

The score is held back primarily by weak financial performance (very small revenue base, sizable losses, and ongoing cash burn), despite a strong low-leverage balance sheet. Technicals add additional pressure given the downtrend and negative momentum, while valuation is constrained by a negative P/E and no dividend support.

Positive Factors

Low leverage / strong balance sheet

The very low debt relative to equity gives the company durable financial flexibility to fund clinical programs and strategic options over the next several quarters without immediate refinancing risk, reducing likelihood of distress while trials progress.

Proprietary ddRNAi / AAV delivery platform

A specialized ddRNAi platform coupled with AAV delivery is a structural competitive advantage: it targets diseases via durable gene-silencing, enabling differentiated therapeutic approaches and potential long-term value if clinical proof points are achieved.

Improving cash discipline vs prior annual outflow

A reduced operating cash outflow compared with the prior annual pace indicates management is moderating spend or achieving operational efficiencies, extending runway and increasing the likelihood the balance sheet will support near-term development milestones.

Negative Factors

Very small revenue base

With virtually no recurring revenue, the company must rely on its cash reserves or external funding to sustain R&D. This structural lack of commercial cash flow increases dilution or refinancing risk over multiple quarters if clinical progress doesn't attract partners or milestones.

Large and expanding net losses

Rising net losses reflect increasing R&D and operating spend without offsetting revenue, consuming equity capital. Persistent and growing deficits can materially erode the balance sheet over months and necessitate financing that dilutes existing holders or constrains strategic flexibility.

Negative operating and free cash flow

Sustained negative operating and free cash flow means the business is funded by cash reserves. Unless clinical milestones convert to partner funding or revenue, continued burn will shorten runway, making financing timing and terms a persistent structural risk for the next 2–6 months.

Benitec Biopharma Business Overview & Revenue Model

Company Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

How the Company Makes Money

null

Benitec Biopharma Financial Statement Overview

Summary

Balance sheet strength (very low debt vs. equity) provides financial flexibility, but this is offset by very weak operating fundamentals: minimal TTM revenue, large and expanding net losses, and continued negative operating/free cash flow indicating ongoing cash burn.

Income Statement

TTM (Trailing-Twelve-Months) revenue remains very small ($0.6M) and profitability is deeply negative, with a large net loss (about $50.9M) and extremely weak margins. While this is not unusual for early-stage biotech, losses have expanded versus the last annual period (net loss ~$37.9M in 2025), indicating rising spend without a meaningful revenue base yet.

Balance Sheet

The balance sheet is a relative strength: leverage is very low in TTM (Trailing-Twelve-Months) with total debt of about $1.0M against ~$187.4M of equity, leaving ample financial flexibility. The key weakness is continued negative returns on equity driven by ongoing losses, so the strong capital position is being consumed over time if profitability does not improve.

Cash Flow

Cash generation is weak, with TTM (Trailing-Twelve-Months) operating cash flow and free cash flow both around -$18.7M to -$18.8M, reflecting a business that is still funding operations through its balance sheet. Free cash flow also deteriorated versus the prior period (negative growth), although cash burn is lower than the 2025 annual operating cash outflow (~-$23.6M), suggesting some improvement in cash discipline.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	556.00K	0.00	0.00	75.00K	73.00K	59.00K
Gross Profit	-66.00K	-396.00K	-343.00K	-306.00K	64.00K	-64.00K
EBITDA	-51.33M	-41.70M	-21.41M	-19.15M	-17.85M	-13.45M
Net Income	-46.30M	-37.92M	-21.75M	-19.56M	-18.21M	-13.88M
Balance Sheet
Total Assets	190.68M	99.59M	52.21M	4.46M	5.97M	21.38M
Cash, Cash Equivalents and Short-Term Investments	188.79M	97.74M	50.87M	2.48M	4.06M	19.77M
Total Debt	987.00K	849.00K	284.00K	559.00K	811.00K	213.00K
Total Liabilities	3.32M	2.30M	4.96M	4.26M	3.09M	1.37M
Stockholders Equity	187.36M	97.30M	47.25M	202.00K	2.88M	20.01M
Cash Flow
Free Cash Flow	-18.76M	-23.61M	-19.58M	-18.01M	-15.91M	-13.05M
Operating Cash Flow	-18.74M	-23.59M	-19.40M	-18.01M	-15.90M	-12.83M
Investing Cash Flow	-17.47K	-18.00K	-179.00K	-1.00K	-13.00K	-221.00K
Financing Cash Flow	130.92M	70.48M	68.03M	16.02M	0.00	22.52M

Benitec Biopharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.75
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Neutral. The current price of 11.75 is above the 20-day moving average (MA) of 11.14, above the 50-day MA of 11.75, and below the 200-day MA of 13.10, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 52.31 is Neutral, neither overbought nor oversold. The STOCH value of 57.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BNTC.

Benitec Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BNTC	49 Neutral	$403.66M	-13.08	-38.92%	―	―	80.95%
ASMB	49 Neutral	$444.70M	-5.33	-59.01%	―	31.30%	32.79%
RCKT	49 Neutral	$513.53M	-2.29	-65.76%	―	―	18.39%
FDMT	47 Neutral	$424.90M	-2.14	-47.27%	―	―	―
TVRD	46 Neutral	$36.77M	-16.53	-97.61%	―	-53.67%	86.75%
AURA	42 Neutral	$377.21M	-3.90	-69.67%	―	―	-11.41%